JUL 04, 2018 1:05 AM PDT

Increased Dose of Drug 'Rifampin' Effective in Eliminating Tuberculosis Bacterium

WRITTEN BY: Nouran Amin

This study finds higher doses of rifampin may lead to faster elimination of TB bacteria. Credit: ATS via MedicalXpress.com

According to a randomized controlled trial, a TB drug by the name ‘Rifampin’ was seen to effectively kill TB bacteria in sputum cultures when administered at an increased dose per day.

In the publication "Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis: A Randomized Controlled Trial," Gustavo E. Velásquez, MD, MPH, at Brigham and Women's Hospital in Boston, along with co-authors report on findings from a phase 2 trial investigated in Lima, Peru, which included 180 adults with new, drug-susceptible TB.

Recent studies before this publication examined whether intermittent delivery of increased doses of rifampin was effective in eradicating the TB bacterium and found that intermittent higher doses were more toxic than reduced doses of rifampin.

However, the authors of the current study believe that their research findings are encouraging for TB patients because it suggests a high enough dose of rifampin per day is possible with minimal side effects and given under six months.

"Six months of treatment with four drugs—often delivered with support and supervision—represents a substantial burden on the healthcare system, as well as on the patient," explains Dr. Velásquez. "Patients who cannot complete the full regimen may not be cured, which permits ongoing transmission and the development of drug-resistant TB."

In the study, participants were randomized equally to either receive 1.) a standard dose of 10 mg/kg/day of rifampin or 2.) higher doses of 15 and 20 mg/kg/day, along with standard doses of the other first-line anti-TB drugs (isoniazid, pyrazinamide, ethambutol), during the first eight weeks of intensive therapy. The study found that each five mg/kg/day increase in a rifampin dose also increased the eradication rate of TB bacteria from the sputum.

In particular, the effectiveness of an increased dose did not show evidence of grade two or higher rifampin-related adverse events. The two commonly reported negative events of increased rifampin doses are liver toxicity and a flu-like syndrome. However, the flu-like syndrome was not seen in this particular study.

Additionally, after an eight-week intensive treatment phase, the clinical trial did not find a great difference in the rates of culture conversion among the trial arms.

"The difference was too modest at the tested doses for successful treatment shortening," Dr. Velásquez said. "However, these results, taken together with other recently published reports, support efforts to increase doses of rifampin to 35 mg/kg/day and possibly higher until the maximum tolerated dose is identified."

Source: American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, MedicalXpress

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 26, 2020
Neuroscience
JAN 26, 2020
Gene Mutation Identified that Protects Agaist Dementia
For over two decades, researchers have been studying an extended family of over 1,200 people from Columbia known for having a rare genetic mutation that le...
JAN 26, 2020
Drug Discovery & Development
JAN 26, 2020
Stroke Drug Enhances Stem Cell Therapies for Spinal Cord Injuries
Using rat models of spinal cord injuries, Yasuhiro Shiga, MD, PhD, thought treating them with stem cell therapy would point to nowhere but the nature of re...
JAN 26, 2020
Technology
JAN 26, 2020
Can a 'Lemon' help develop new drugs?
Although artificial intelligence has many advantages in the drug discovery process, challenges still remain--one being the ability for machine learning to ...
JAN 26, 2020
Drug Discovery & Development
JAN 26, 2020
Effective Therapeutic Approved for Migraines
The U.S Food and Drug Administration has now approved a new medication for migraines. The drug is called ‘ubrogepant (Ubrelvy)’ and comes in th...
JAN 26, 2020
Drug Discovery & Development
JAN 26, 2020
Promising Treatment for Dementia: Antibiotics
A class of antibiotics, known as the ‘aminoglycosides’ may serve as a promising treatment for frontotemporal dementia—according to resear...
JAN 26, 2020
Drug Discovery & Development
JAN 26, 2020
Drug Combo Targets Osteoarthritis
Individuals suffering from osteoarthritis often face challenges of limited treatment options mainly pain relievers or joint replacement surgery. However, s...
Loading Comments...